纤维蛋白原浓缩物预防重型颅脑创伤高纤溶风险患者低纤维蛋白原血症的效果:单中心前后对照研究
该单中心前后对照研究分两部分:第一部分回顾2016年4月至2019年3月78例重型颅脑创伤(sTBI)成人患者,其中23例入院后3-6小时未能维持纤维蛋白原≥150 mg/dL,识别出D-二聚体>50 μg/mL、入院纤维蛋白原<200 mg/dL、凹陷性颅骨骨折及多发伤为重度纤溶(HF)危险因素;第二部分将2019年4月至2021年3月存在至少一项上述危险因素并接受纤维蛋白原浓缩物(FC)治疗的15例患者,与2016年4月至2019年3月未接受FC的46例高危患者比较,FC组14/15例维持纤维蛋白原≥150 mg/dL(OR 0.07,95%CI 0.01-0.59),但30天死亡率无显著差异。作者认为FC可能有助于快速纠正低纤维蛋白原血症。
要点
- sTBI患者入院时D-二聚体>50 μg/mL、纤维蛋白原<200 mg/dL、凹陷性颅骨骨折或多发伤是重度纤溶的危险因素。
- 对存在至少一项上述危险因素的高危sTBI患者,FC组14/15例在入院后3-6小时维持纤维蛋白原≥150 mg/dL,非FC组为46例中未报告具体例数。
- FC组与非FC组相比,维持纤维蛋白原≥150 mg/dL的OR为0.07(95%CI 0.01-0.59)。
- FC组与非FC组30天死亡率无显著差异。
- 作者认为FC可能有助于快速纠正正在发生的低纤维蛋白原血症。
适用人群与场景
- 第一部分:2016年4月至2019年3月在本院连续收治的成人重型颅脑创伤(sTBI)患者,按常规方案输血。
- 第二部分:2019年4月至2021年3月存在至少一项第一部分识别的重度纤溶危险因素的sTBI患者(FC组),与2016年4月至2019年3月存在高危因素但未接受FC的患者(非FC组)比较。
诊断标准与关键阈值
- 重度纤溶危险因素:入院时D-二聚体>50 μg/mL、入院时纤维蛋白原<200 mg/dL、凹陷性颅骨骨折、多发伤。
- 高危患者定义:存在至少一项上述危险因素。
- 主要结局:入院后3-6小时维持纤维蛋白原≥150 mg/dL。
处置流程与药物剂量
- FC组患者接受纤维蛋白原浓缩物(FC)治疗,具体剂量、给药途径和频次原文未报告。
- 非FC组接受常规输血治疗。
研究设计与关键结果
- 研究类型:单中心前后对照研究;第一部分回顾性分析78例sTBI成人患者,其中23例入院后3-6小时未维持纤维蛋白原≥150 mg/dL。
- 第一部分识别出重度纤溶危险因素:入院时D-二聚体>50 μg/mL、入院时纤维蛋白原<200 mg/dL、凹陷性颅骨骨折、多发伤。
- 第二部分FC组15例中14例维持纤维蛋白原≥150 mg/dL,非FC组46例(具体维持例数原文未报告),OR 0.07(95%CI 0.01-0.59)。
- FC组与非FC组纤维蛋白原水平有显著差异,但30天死亡率无显著差异。
证据类型、等级与局限
- 证据类型:单中心前后对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对存在入院时D-二聚体>50 μg/mL、入院时纤维蛋白原<200 mg/dL、凹陷性颅骨骨折或多发伤等重度纤溶危险因素的sTBI患者,FC给药可能有助于快速纠正正在发生的低纤维蛋白原血症。
- FC给药对30天死亡率无显著影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coagulopathy is often observed in severe traumatic brain injury (sTBI), and hyperfibrinolysis (HF) is associated with a poor prognosis. Although the efficacy of fibrinogen concentrate (FC) in multiple trauma has been reported, its efficacy in sTBI is unclear. Therefore, we delineated severe HF risk factors despite fresh frozen plasma transfusion. Using these risk factors, we defined high-risk patients and determined whether FC administration to this group improved fibrinogen level.
METHODS: In the first part of this study, successive adults with sTBI treated at our hospital between April 2016 and March 2019 were reviewed. Patients underwent transfusion as per our conventional protocol and were divided into two groups based on whether fibrinogen levels of ≥ 150 mg/dL were maintained 3-6 h after arrival to delineate the risk factors of severe HF. In the second part of the study, we conducted a before-and-after study in patients with sTBI who were at a higher risk for severe HF (presence of at least one of the risk factors identified in the first part of the study), comparing those treated with FC between April 2019 and March 2021 (FC group) with those treated with conventional transfusion before FC between April 2016 and March 2019. The primary outcome was maintenance of fibrinogen levels, and the secondary outcome was 30-day mortality.
RESULTS: In the first part of the study, 78 patients were included. Twenty-three patients did not maintain fibrinogen levels ≥ 150 mg/dL. A D-dimer level on arrival > 50 μg/mL, a fibrinogen level on arrival < 200 mg/dL, depressed skull fracture, and multiple trauma were severe HF risk factors. In the second part, compared with 46 patients who were identified as being at high risk for severe HF but were not administered FC (non-FC group), fibrinogen levels ≥ 150 mg/dL 3-6 h after arrival were maintained in 14 of 15 patients in the FC group (odds ratio: 0.07; 95% confidence interval: 0.01-0.59). Although there were significant differences in fibrinogen levels, no significant differences were observed in terms of 30-day mortality between the groups.
CONCLUSIONS: Coagulation abnormalities on arrival, severe skull fracture, and multiple trauma are severe HF risk factors. FC administration may contribute to rapid correction of developing hypofibrinogenemia.
参考来源
- Fujiwara G, Murakami M, Ishii W, et al. Effectiveness of Administration of Fibrinogen Concentrate as Prevention of Hypofibrinogenemia in Patients with Traumatic Brain Injury with a Higher Risk for Severe Hyperfibrinolysis: Single Center Before-and-After Study. Neurocrit Care. 2022. PMID: 36324002. doi:10.1007/s12028-022-01626-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。